EyePoint (EYPT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$2.8M

Revenue (quarter)

$507,000.00

Revenue growth (year over year)

−90.49%

Gross profit (trailing twelve months)

$1.2M

Gross margin

41.57%

Net income (trailing twelve months)

−$306.6M

Net income (quarter)

−$94.5M

Net income growth (year over year)

−58.97%

Net margin

−10998.67%

Return on equity

−148.70%

EPS (trailing twelve months)

−$3.75

Book value per share

$1.96

P/E (trailing twelve months)

—

Price to book

1.61

Debt to assets

27.07%

Payout ratio

—

Dividend yield

—

Company profile

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

• Is EyePoint (EYPT) profitable?

  No. EyePoint reported a net loss of $306.6M over the trailing twelve months.

• How much revenue does EyePoint (EYPT) make?

  EyePoint generated $2.8M in revenue over the trailing twelve months, down 90.49% year over year.

• How do I buy stock in EyePoint (EYPT)?

  EYPT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.